Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.65 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.60 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23598453 | 1.00 | EGFR (0.65) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL19003389 | 1.00 | EGFR (0.65) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL24548651 | 0.99 | EGFR (0.64) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL24157885 | 0.96 | PTGER2 (0.71) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL19003325 | 0.96 | PTGER2 (0.71) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL19003414 | 0.96 | PTGER2 (0.71) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL24158138 | 0.96 | EGFR (0.61) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL19003327 | 0.96 | PTGER2 (0.71) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL19003323 | 0.96 | PTGER2 (0.71) | EGFRPTGER2EPHA2NFKBIAAKT1 | |
| SCHEMBL23598434 | 0.94 | PTGER2 (0.63) | EGFRPTGER2EPHA2NFKBIAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195524-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND MANAGEMENT OF NEURODEGERATIVE DISEASES | UNIV SOUTH FLORIDA (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220195524-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND MANAGEMENT OF NEURODEGERATIVE DISEASES | PSEN2, CLN6, PSEN1 | EGFR 3609/4885PTGER2 3674/4885EPHA2 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.